comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists outcome studies receptor Effects of tirzepatide, a dual
Description
Hsia DS, Grove O, Cefalu WT
doi:10.3390/medicina60030357 Hellstrm PM, Nslund E, Edholm T, et al
10.1038/ncomms9918
doi: 10.2337/diabetes.52.1.102 125 FarillaLHuiHBertolottoCKangEBulottaADi MarioUet al
According to a recently released approval letter, the FDA has instructed Eli Lilly to study potential risks associated with Foundayo, especially those related to the heart and liver
The impact of age on weight reduction efficacy Covariate analysis identified age as a significant factor affecting the weight reduction efficacy of GLP-1RA drugs
